Microalgae-based drug delivery microspheres for treatment of hyperuricemia with renal injury
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Gout, Hyperuricemia, Uric Acid · Muscle and Compartmental Disorders · Poisoning and overdose treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (53)
Show source-provided references
1. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors10.1038/s41584-020-0441-1 ↗
2. Sonneratia apetala seed oil attenuates potassium oxonate/hypoxanthine-induced hyperuricemia and renal injury in mice10.1039/D1FO01830B ↗
4. Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice10.1016/j.biopha.2019.109195 ↗
5. Lacticaseibacillus rhamnosus Fmb14 prevents purine induced hyperuricemia and alleviate renal fibrosis through gut-kidney axis10.1016/j.phrs.2022.106350 ↗
6. Alistipes indistinctus-derived hippuric acid promotes intestinal urate excretion to alleviate hyperuricemia10.1016/j.chom.2024.02.001 ↗
7. Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis10.1039/D0FO03199B ↗
8. Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway10.1016/j.ejphar.2021.174592 ↗
9. Serum Urate–Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial10.1002/art.42447 ↗
10. Phloretin ameliorates hyperuricemia-induced chronic renal dysfunction through inhibiting NLRP3 inflammasome and uric acid reabsorption10.1016/j.phymed.2019.153111 ↗
11. Coptisine protects against hyperuricemic nephropathy through alleviating inflammation, oxidative stress and mitochondrial apoptosis via PI3K/Akt signaling pathway10.1016/j.biopha.2022.113941 ↗
12. Study on the mechanism of Phellinus igniarius total flavonoids in reducing uric acid and protecting uric acid renal injury in vitro
13. Gout therapeutics and drug delivery10.1016/j.jconrel.2023.09.011 ↗
14. Mechanisms and rationale for uricase use in patients with gout10.1038/s41584-023-01006-3 ↗
15. Comparison of 3 hyperuricemia mouse models and evaluation of food-derived anti-hyperuricemia compound with spontaneous hyperuricemia mouse model10.1016/j.bbrc.2022.09.043 ↗
16. Anti-inflammatory activities of Euglena gracilis extracts10.3390/microorganisms9102058 ↗
17. Euglena as a potential natural source of value-added metabolites. A review10.1016/j.algal.2018.11.024 ↗
18. Oral administration of green algae, Euglena gracilis, inhibits hyperglycemia in OLETF rats, a model of spontaneous type 2 diabetes10.1039/C6FO00606J ↗
19. Renoprotective effects of paramylon, a β-1, 3-D-Glucan isolated from Euglena gracilis Z in a rodent model of chronic kidney disease10.1371/journal.pone.0237086 ↗
20. Oral Administration of Water Extract from Euglena gracilis Alters the Intestinal Microbiota and Prevents Lung Carcinoma Growth in Mice10.3390/nu14030678 ↗
21. Purine absorption inhibitor and blood uric acid level reducing agent
22. Luteolin can ameliorate renal interstitial fibrosis-induced renal anaemia through the SIRT1/FOXO3 pathway10.1039/D2FO02477B ↗
23. Cerium–Luteolin Nanocomplexes in Managing Inflammation-Related Diseases by Antioxidant and Immunoregulation10.1021/acsnano.3c09528 ↗
24. Inhibition of xanthine oxidase-catalyzed xanthine and 6-mercaptopurine oxidation by luteolin, naringenin, myricetin, ampelopsin and their conjugated metabolites10.1016/j.biopha.2023.115548 ↗
25. Nano-scale drug delivery systems for luteolin: advancements and applications10.1039/D3TB01753B ↗
26. ROS-responsive nanoparticles for oral delivery of luteolin and targeted therapy of ulcerative colitis by regulating pathological microenvironment
27. Regulating Type H Vessel Formation and Bone Metabolism via Bone-Targeting Oral Micro/Nano-Hydrogel Microspheres to Prevent Bone Loss10.1002/advs.202207381 ↗
28. Colon-Targeted Adhesive Hydrogel Microsphere for Regulation of Gut Immunity and Flora10.1002/advs.202101619 ↗
29. Microfluidic Encapsulation of Exosomes Derived from Lipopolysaccharide-Treated Mesenchymal Stem Cells in Hyaluronic Acid Methacryloyl to Restore Ovarian Function in Mice
30. Hydrogels Based on Schiff Base Linkages for Biomedical Applications
31. Characteristic and Chondrogenic Differentiation Analysis of Hybrid Hydrogels Comprised of Hyaluronic Acid Methacryloyl (HAMA), Gelatin Methacryloyl (GelMA), and the Acrylate-Functionalized Nano-Silica Crosslinker10.3390/polym14102003 ↗
32. Injectable Microgels with Hybrid Exosomes of Chondrocyte-Targeted FGF18 Gene-Editing and Self-Renewable Lubrication for Osteoarthritis Therapy10.1002/adma.202312559 ↗
33. Angiogenic Microspheres for the Treatment of a Thin Endometrium10.1021/acsbiomaterials.1c00615 ↗
34. Injectable hydrogel microspheres with self-renewable hydration layers alleviate osteoarthritis10.1126/sciadv.abl6449 ↗
35. Charge-Guided Micro/Nano-Hydrogel Microsphere for Penetrating Cartilage Matrix10.1002/adfm.202107678 ↗
36. Orally administrated nucleotide-delivery particles from microfluidics for inflammatory bowel disease treatment
37. Injectable Stem Cell-Laden Photocrosslinkable Microspheres Fabricated Using Microfluidics for Rapid Generation of Osteogenic Tissue Constructs10.1002/adfm.201504943 ↗
38. Foundations of gastrointestinal-based drug delivery and future developments10.1038/s41575-021-00539-w ↗
39. Effect of 8-Azaguanine on Phosphorylation of Purines in Astasia and Euglena10.1016/S0021-9258(18)97080-8 ↗
40. Ribonuclease of Euglena gracilis10.1126/science.132.3442.1835 ↗
41. Luteolin, a flavonoid, as an anticancer agent: A review10.1016/j.biopha.2019.108612 ↗
42. Metformin prevents methylglyoxal-induced apoptosis by suppressing oxidative stress in vitro and in vivo10.1038/s41419-021-04478-x ↗
43. From purines to purinergic signalling: molecular functions and human diseases10.1038/s41392-021-00553-z ↗
44. Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?10.1016/j.phrs.2022.106407 ↗
45. Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review10.1007/s40265-023-01944-y ↗
46. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout10.1056/NEJMoa1710895 ↗
47. Scutellarin Ameliorates Renal Injury via Increasing CCN1 Expression and Suppressing NLRP3 Inflammasome Activation in Hyperuricemic Mice
48. The emerging role of the inflammasome in kidney diseases10.1097/01.mnh.0000444814.49755.90 ↗
49. A role for mitochondria in NLRP3 inflammasome activation10.1038/nature09663 ↗
50. Regulation of Uric Acid Excretion by the Kidney10.1007/s11926-012-0240-z ↗
51. RETRACTED: Depleting microRNA-183-3p improves renal tubulointerstitial fibrosis after acute kidney injury via SIRT1/PUMA/FOXO3a deacetylation10.1016/j.lfs.2021.119017 ↗
52. Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia10.1002/art.41067 ↗
53. Pancreatic cancer cell line in responsive hydrogel microcapsules for drug evaluation10.1002/VIW.20230048 ↗